Fernandez-Sojo J., Delgadillo J., Vives J., Rodriguez L., Mendoza A., Azqueta C., Garcia-Buendia A., Valdivia E., Martorell L., Rubio-Lopez N., Linares M., Alonso S., Ancochea A., Garcfa-Rey, E, García-Muñoz N., Medina L., Querol S.. A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank experience. CYTOTHERAPY. 2023; 25(1)DOI:10.1016/j.jcyt.2022.07.011. PMID:36041984. IF:3.700(Q1/3D).

Izquierdo, CP, Mingot-Castellano, ME, Fuentes, AEK, Peinado, JGA, Cid, J, Jimenez, MM, Valcarcel, D, Gomez-Segui, I, de la Rubia, J, Martin, P, Goterris, R, Hernandez, L, Tallon, I, Varea, S, Fernandez, M, Garcia-Munoz, N, Vara, M, Zarzoso, MF, Garcia-Candel, F, Paciello, ML, Garcia-Garcia, I, Zalba, S, Campuzano, V, Gala, JM, Estevez, JV, Jimenez, GM, Lorenzo, JLL, Arias, EG, Freiria, C, Sole, M, Idrovo, LFA, Castellet, JCH, Cruz, N, Lavilla, E, PTrez-Montana, A, Atucha, JA, Beltran, MEM, Macias, JRM, Salinas, R, del Rio-Garma, J. Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Advances. 2022; 6(24)DOI:10.1182/bloodadvances.2022008028. PMID:35930694. IF:7.500(Q1/2D).

Fernandez-Sojo, J, Horton, R, Cid, J, Azqueta, C, Garcia-Buendia, A, Valdivia, E, Martorell, L, Rubio-Lopez, N, Codinach, M, Aran, G, Marsal, J, Mussetti, A, Martino, R, Diaz-de-Heredia, C, Ferra, C, Valcarcel, D, Linares, M, Ancochea, A, Garcia-Rey, E, Garcia-Munoz, N, Medina, L, Carreras, E, Villa, J, Lozano, M, Gibson, D, Querol, S. Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. BONE MARROW TRANSPLANTATION. 2022; 57(10)DOI:10.1038/s41409-022-01750-2. PMID:35804055. IF:4.800(Q1/2D).

Fernandez-Sojo, J, Cid, J, Azqueta, C, Valdivia, E, Martorell, L, Codinach, M, Marsal, J, Mussetti, A, Esquirol, A, Trabazo, M, Benitez, MI, Ferra, C, Fox, ML, Linares, M, Alonso, E, Garcia-Rey, E, Garcia-Munoz, N, Medina, L, Castillo-Flores, N, Vall-Llovera, F, Garcia, A, Pinacho, A, Talarn, C, Arroba, JG, Coll, R, Santos, M, Valero, O, Carreras, E, Lozano, M, Querol, S. Post thawing viable CD34+Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(8)DOI:10.1038/s41409-022-01722-6. PMID:35614316. IF:4.800(Q1/2D).